ZNF224 and chronic myelogenous leukemia, BCR-ABL1 positive: Our previous findings demonstrated that Bcr-Abl fusion protein negatively regulates the expression of the pro-apoptotic transcription factor ZNF224 in CML and accordingly Bcr-Abl inhibition by Imatinib and second-generation tyrosine kinase inhibitors (TKIs) Dasatinib and Nilotinib increase ZNF224 expression [25].